
Prediction: 2 Stocks That Will Be Worth More Than Nvidia 5 Years From Now
Tesla's robotaxi could change the face of the company.
Meta Platforms' AI advantage and low valuation could lead to a massive surge in the stock price.
Admittedly, trying to ponder stocks that might become worth more than Nvidia may seem unimaginable. When demand for AI accelerators surged out of nowhere, so did Nvidia stock, and it is now a stock with a $3.85 trillion market cap, the world's largest.
However, looking to the future, investors may begin to consider which stocks might outpace Nvidia over the next five years. While a lot could happen over that period, these are likely the stocks with the best chance of surpassing Nvidia.
Tesla
Admittedly, Tesla 's (NASDAQ: TSLA) current business does not look like a record breaker. Automobile sales have fallen recently, and its P/E ratio of 176 is pricey, especially considering its forward P/E ratio of 172 may imply little additional near-term upside.
Still, investors should examine why Tesla trades at a 172 forward multiple, and the answer is likely autonomous driving. Tesla has invested heavily in AI and robotics to develop its platform. It has also begun to roll out robotaxis on the road in Austin, Texas. To that end, Tesla just demonstrated a fully autonomous delivery of a Model Y to a customer 30 minutes away from its Gigafactory in that city.
Cathie Wood's team at Ark Invest saw that breakthrough coming. Amid that research, Ark Invest forecast a $2,900 per share price target for the company by 2029. That would amount to a market cap of $9.3 trillion, far above Nvidia's current market cap.
Why so high? Ark Invest believes that by 2029, its self-driving platform revenue will surpass the revenue earned from automobile sales and predicts the robotaxi will make up 63% of the company's revenue by that year.
Indeed, the robotaxi trials still need to succeed, and Tesla faces competition from Uber, Alphabet 's Waymo, and platforms like the ones being developed by Nvidia and Qualcomm.
Still, its combined development of cars and the platforms that drive them may give Tesla a leg up on its way to surpassing the AI chip giant. That success should also dramatically reduce its P/E ratio, likely serving as a catalyst for a much higher stock price.
Meta Platforms
Meta Platforms (NASDAQ: META) has built its company on dominating social media. Its social media platforms now draw over 3.4 billion people daily to at least one of its platforms. With that popularity, the digital advertising business built around those users has given it a market cap of almost $1.86 trillion, approximately half of Nvidia's size.
Unfortunately for the Facebook parent, its user base now makes up over 40% of the world's population, which will probably mean slower growth for its digital ad business moving forward.
However, its aforementioned user base has given the company a treasure trove of user data that is likely unmatched by any other company. Since the data is likely to be of a more personal nature than data compiled by Google or Apple, Meta likely holds a competitive advantage. With that, it plans to apply that data to build its strength in the AI realm.
To achieve this, it is on track to spend between $64 billion and $72 billion this year alone to invest in this business. Much of that will fund a data center building binge, including a $10 billion, four million square foot facility in Louisiana.
Additionally, Meta is in a strong position from a valuation standpoint. Its P/E ratio of 29 closely approximates the S&P 500 average and is far below Nvidia's 51 earnings multiple. The price-to-sales (P/S) ratio confirms this discount, as Meta's sales multiple of 11 is far below Nvidia's P/S ratio of 26.
Indeed, Meta will have to prove itself. For now, its 16% revenue growth in the first quarter of 2025 is far below Nvidia's 69% increase in the first quarter of fiscal 2026 (ended April 27). Nonetheless, if Meta's AI strategy succeeds, its relatively low valuation and value in the AI market could make it a much larger company over the next five years.
Don't miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $407,818!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,330!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $692,914!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
See the 3 stocks »
*Stock Advisor returns as of June 30, 2025
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Will Healy has positions in Qualcomm and Uber Technologies. The Motley Fool has positions in and recommends Alphabet, Apple, Meta Platforms, Nvidia, Qualcomm, Tesla, and Uber Technologies. The Motley Fool has a disclosure policy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
2 hours ago
- Globe and Mail
2 Dividend Stocks to Buy for Decades of Passive Income
Key Points Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits for a long time to come. That's thanks to their solid businesses and promising product pipelines. In 2013, AbbVie (NYSE: ABBV) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (NYSE: ABT). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes. That likely won't change soon. These healthcare leaders should continue to perform well and reward shareholders with dividend increases for a long time. Read on to find out more. 1. AbbVie AbbVie is a pharmaceutical leader with a large portfolio of approved products, none more important than a duo of immunology medicines: Skyrizi and Rinvoq. In the first quarter, the company's revenue increased by 8.4% year over year to $13.3 billion, while its adjusted earnings per share came in at $2.46, 6.5% higher than the year-ago period. These results are all the more impressive considering AbbVie faced a major patent cliff just two years ago; however, it has since recovered, largely thanks to Skyrizi and Rinvoq. The former generated $3.4 billion in sales during the period, representing a 70.5% year-over-year increase. Rinvoq's revenue came in at $1.7 billion, 57.2% higher than the year-ago period. Management predicts their combined annual sales will exceed $31 billion by 2027. Not only is that significantly higher than the $17.7 billion they racked up last year, it's also $4 billion higher than their previous guidance. Skyrizi and Rinvoq are expected to drive top-line growth well into the 2030s. Although they will eventually lose patent protection, they demonstrate AbbVie's ability to navigate even the biggest patent cliffs, a quality that is essential for any pharmaceutical company to thrive over the long term. AbbVie has other products that help drive revenue growth, and, equally important, it has a deep pipeline that it routinely strengthens through acquisitions. In March, the company announced a licensing deal with Denmark-based Gubra A/S for GUB014295, an investigational weight management therapy. AbbVie paid $350 million up front for this candidate, with potential milestones of $1.9 billion, not including royalties. AbbVie entered the fast-growing weight loss market with this move; GUB014295 might not pan out, but AbbVie's large pipeline, with approximately 90 products in development, should allow it to launch brand-new products frequently, navigate patent cliffs, and remain successful over the long run. Now turning to the company's dividend, AbbVie has increased its payouts by 310% since 2013. And counting the time it spent under Abbott Laboratories' name, AbbVie is a Dividend King with 53 consecutive years of payout increases. These facts, from AbbVie's underlying business to the company's dividend track record, point to a company capable of sustaining a passive income program for a long time. 2. Abbott Laboratories Abbott Laboratories is best known for its leadership in the medical device space, where it markets dozens of products across multiple therapeutic areas. The company also operates a diagnostic business and has a presence in the pharmaceutical and nutrition industries. Abbott Laboratories' operations are diversified, which can help it overcome challenges in specific segments. That's one of the company's strengths. Here's another: Abbott Laboratories has been a leader in the highly regulated healthcare sector for decades. The company has built a solid reputation with physicians and consumers, all of whom are more likely to gravitate toward the brands they know and trust. In the medical device field, Abbott is a trusted brand. And thanks to its vast portfolio, it generates consistent revenue and earnings. Abbott's biggest growth driver in recent years has been its diabetes care segment, led by its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. As the company noted, the FreeStyle Libre has become the most successful medical device in history in terms of dollar sales. That's no small feat. Yet there is still massive whitespace ahead, since only a small portion of the world's diabetics use CGM technology despite its advantages. Abbott's work in this niche should provide a powerful long-term tailwind, but there will be many others. The company boasts other growth drivers, including its structural heart segment, where it markets a range of successful devices, such as its MitraClip device, a leader in its mitral valve repair niche. Beyond any single product, Abbott Laboratories has a proven track record as an innovator and should continue launching newer and better ones. Lastly, Abbott is also a Dividend King, and over the past decade, it has increased its payouts by almost 146%. Abbott Laboratories' business is built to last. Investors who purchase the company's shares today can expect consistent dividend growth over the long term. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025


CBC
3 hours ago
- CBC
Elon Musk announces new 'America Party' after Trump's massive spending bill becomes law
The dispute between U.S. Republican President Donald Trump and his main campaign financier Elon Musk took another fractious turn on Saturday when the space and automotive billionaire announced the formation of a new political party, saying Trump's "big, beautiful" tax bill would bankrupt America. A day after asking his followers on his X platform whether a new U.S. political party should be created, Musk declared in a post on Saturday: "Today, the America Party is formed to give you back your freedom." "By a factor of 2 to 1, you want a new political party and you shall have it!" he wrote. The announcement from Musk comes after Trump signed his self-styled "big, beautiful" tax-cut and spending bill into law on Friday, which Musk fiercely opposed. WATCH | What drove a wedge between Trump and Musk: Will Donald Trump and Elon Musk destroy each other? 25 days ago Duration 25:36 Musk, who became the word's richest man thanks to his Tesla car company and his SpaceX satellite firm, spent hundreds of millions on Trump's re-election and led the Department of Government Efficiency, aimed at slashing government spending, from the start of the president's second term. The first sign of investor dissatisfaction with Musk's announcement followed later in the day. Investment firm Azoria Partners will postpone the listing of a Tesla exchange-traded fund, Azoria CEO James Fishback said in a post on X. Fishback is asking Tesla's board to clarify Musk's political ambitions and said the new party undermines the confidence shareholders had that he would be focusing more on the company after leaving government service in May. Musk said previously that he would start a new political party and spend money to unseat lawmakers who supported the bill. Trump earlier this week threatened to cut off the billions of dollars in subsidies that Musk's companies receive from the federal government. Republicans have expressed concern that Musk's on-again, off-again feud with Trump could hurt their chances to protect their majority in the 2026 midterm congressional elections. Asked on X what was the one thing that made him go from loving Trump to attacking him, Musk said: "Increasing the deficit from an already insane $2T under Biden to $2.5T. This will bankrupt the country." There was no immediate comment from Trump or the White House on Musk's announcement. The feud with Trump, often described as one between the world's richest man and the world's most powerful, has led to several precipitous falls in Tesla's share price. The stock soared after Trump's November re-election and hit a high of more than $488 US in December, before losing more than half of its value in April and closing out last week at $315.35 US. Despite Musk's deep pockets, breaking the Republican-Democratic duopoly will be a tall order, given that it has dominated American political life for more than 160 years, while Trump's approval ratings in polls in his second term have generally held firm above 40 per cent, despite often divisive policies.


CTV News
3 hours ago
- CTV News
Trump's ‘reciprocal' tariff pause is about to expire. Cue the confusion
The 90-day deadline U.S. President Donald Trump set for countries to make trade deals with the United States or risk substantially higher tariffs is just days away. What will happen after that's reached at 12:01 a.m. ET on July 9 is anyone's best guess. The stakes could not be higher, with the entire global economy on notice. On April 2, a date Trump dubbed 'Liberation Day,' he unveiled new, 'reciprocal' tariff rates for key US trading partners, with some levies as high as 50 per cent. Collectively, the rates were the highest the US has charged on foreign goods in over a century. Economists quickly sounded alarms about a recession hitting not just certain countries, but rather the whole world. As the tariffs went into effect on April 9, they sparked a sell-off on Wall Street and the bond market rebelled, forcing Trump to announce a three-month pause to give countries more time to solidify deals with the US, saying investors 'were getting a little bit yippy, a little afraid.' Since then, almost all goods the US imports have been subject to a minimum 10 per cent tariff. Stocks, meanwhile, have not only recovered all those losses but have set multiple new record highs. And inflation has barely budged. But if tariffs start to rise again and inflation roars back, those gains could quickly get erased all over again. After months of meeting with foreign government officials and countless claims that several trading partners were on the cusp of completing deals, only three have been announced. One of those, with Vietnam, has yet to be finalized and few details are known about it. Still, the Trump administration is advertising that a flurry of deals are forthcoming. At the same time, the president has threatened to send letters to countries that don't ink deals, telling them the rate at which their exports to the US will be taxed. Leading up to July 9, Trump administration officials threatened to simply return to April tariff rates, or possibly even higher levies. They also floated the possibility of extending the pause for countries 'negotiating in good faith,' without defining what that means or which it includes. It's not clear where Trump, who will get the ultimate say, stands. 'We can do whatever we want. We could extend it; we could make it shorter,' Trump recently said. 'I'd like to make it shorter. I'd like to just sent letters out to everybody, 'Congratulations, you're paying 25 per cent.'' 'We'll look at how a country treats us — are they good, are they not so good — some countries we don't care, we'll just send a high number out,' Trump also recently said. On Friday, he said he'd begin sending letters over the coming days. 'They'll range in value from maybe 60 per cent or 70 per cent tariffs to 10 per cent and 20 per cent tariffs,' Trump said. For many countries, such rates would deal an even bigger economic blow compared to the levels Trump announced in April. But countries may have the opportunity to still negotiate, given Trump said most new rates won't take effect until August 1. America's evolving pain tolerance for higher tariffs The deal Trump announced on Wednesday with Vietnam, which calls for minimum tariffs of 20 per cent on Vietnamese goods, double the rate throughout the three-month pause, has raised the possibility that countries may not be able to score lower rates even if they reach a trade agreement. But considering tariffs on Vietnam were set to rise to a minimum of 46 per cent if the rates Trump announced in April held — which was among the highest Trump announced — 20 per cent suddenly feels like a relief. That may be an intentional strategy on Trump's part, allowing him to stick to his major campaign promise of levying higher tariffs on other nations in an effort to raise revenues and bring manufacturing jobs back to the US. 'On balance, we take the U.S.-Vietnam accord as a positive step toward more durable bilateral deals for the US and toward greater clarity for investors,' Ulrike Hoffmann-Burchardi, global head of equities at UBS Global Wealth Management, said in a note last week. 'Headline risks around trade may persist as negotiations continue, but we think the market impact should moderate as President Trump's negotiating tactics become increasingly familiar,' he said. 'Ultimately, we expect the US administration to prioritize economic stability over more maximalist tariffs, especially ahead of the 2026 midterm elections.' Elisabeth Buchwald, CNN